• What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?

  • Jun 30 2021
  • Duración: 8 m
  • Podcast

What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • During the EHA2021 Virtual Congress, the MDS Hub spoke with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?


    In this podcast, Platzbecker discusses the potential hematologic toxicities associated with the combination of venetoclax and azacitidine, and how to manage these toxicities in patients with high-risk MDS. He highlights the key points of a study presented during EHA2021, including dose modification considerations, overall response rates, infectious complications, and other side effects. Finally, Platzbecker believes this toxicity analysis provides clinically valuable information to doctors and hematologists who are already treating patients with this combination.


    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles